Your Guide to Starting GLP-1 Medications
Everything you need to know to begin your weight loss journey with GLP-1 medications safely and successfully.
Beginning Your Weight Loss Journey
Starting GLP-1 medications is an exciting step toward achieving your health goals. This comprehensive guide walks you through every stage of the process, from getting your initial prescription to understanding what to expect in your first weeks of treatment.
Essential Guides for Beginners
How to Get Prescribed GLP-1 Medications
Step-by-step guide to getting a prescription for weight loss medications including eligibility requirements and consultation process.
What to Expect: First Month on GLP-1s
Detailed guide on what to expect during your first month, including side effects, dosing, and lifestyle adjustments.
Choosing Between Semaglutide and Tirzepatide
Compare the two leading medications to determine which might be the best fit for your weight loss goals.
Finding the Right Healthcare Provider
How to find a qualified healthcare provider who can prescribe and monitor your GLP-1 therapy.
Am I Eligible for GLP-1 Medications?
BMI Requirements
Generally approved for individuals with BMI ≥30 kg/m² (obesity) or BMI ≥27 kg/m² (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, or sleep apnea.
Medical Evaluation
A healthcare provider will review your medical history, current medications, and perform necessary lab tests to ensure GLP-1 medications are safe and appropriate for you.
Contraindications
GLP-1 medications may not be suitable for individuals with personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or severe gastrointestinal disease.
Ready to Get Started?
Begin your weight loss journey with Trimi. Our healthcare providers can evaluate your eligibility and guide you through every step of the process.
Start Your ConsultationMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).